TACE术联合仑伐替尼与联合阿帕替尼治疗中晚期原发性肝癌的效果及安全性比较

肝脏 ›› 2025, Vol. 30 ›› Issue (12): 1647-1651.

TACE术联合仑伐替尼与联合阿帕替尼治疗中晚期原发性肝癌的效果及安全性比较

姚敏, 杨军军, 郭小红, 徐爱兵

226361 南通南通市肿瘤医院/南通大学附属肿瘤医院药学部(姚敏,杨军军,郭小红),介入科(徐爱兵)

收稿日期:2024-12-30 发布日期:2026-02-10
通讯作者: 郭小红,Email:954159397@qq.com
基金资助:
江苏省药学会-恒瑞医院药学基金项目(H202336);江苏省药学会-正大天晴医院药学科研基金项目(Q202236);南通市药物政策与药学服务研究课题项目(2023NTPA09)

Effect and safety of TACE combined with lenvatinib mesylate and combined with apatinib in the treatment of intermediate and advanced primary liver cancer

YAO Min¹, YANG Jun-jun¹, GUO Xiao-hong¹, XU Ai-bing²

1. Department of Pharmacy, Nantong Tumor Hospital/Cancer Hospital Affiliated to Nantong University, Nantong 226361, China;
2. Department of Interventional Radiology, Nantong Tumor Hospital/Cancer Hospital Affiliated to Nantong University, Nantong 226361, China

Received:2024-12-30 Published:2026-02-10
Contact: GUO Xiao-hong,Email:954159397@qq.com

摘要/Abstract

摘要： 目的分析经TACE联合仑伐替尼与联合阿帕替尼治疗中晚期PLC的效果。方法选取2022年1月至2023年12月南通大学附属肿瘤医院收治的85例中晚期PLC患者,按不同治疗方法分为对照组与观察组,对照组(42例)采取TACE术联合阿帕替尼治疗,观察组(43例)采取TACE术联合仑伐替尼,比较疗效。结果观察组客观缓解率(ORR 60.47%)与疾病控制率(DCR 74.42% )均显著优于对照组(ORR 35.71%;DCR 52.38%)(P<0.05)。治疗后,观察组肿瘤标志物水平[CEA(13.36±2.47)ng/mL vs. (19.63±3.14)ng/mL,CA125(52.63±6.89)U/mL vs.(58.49±8.69)U/mL,VEGF(292.69±23.46)ng/mL vs. (341.63±28.48)ng/mL]、肝功能指标[TBil(16.85±3.89)μmol/L vs. (21.78±4.02)μmol/L,ALT(42.63±6.52)U/L vs. (53.69±7.25)U/L,VEGF(38.52±4.69)U/L vs. (48.20±5.06)U/L]以及免疫功能[CD4⁺(46.32±4.87)% vs. (42.69±4.38)%,CD8⁺(22.36±3.25)% vs. (26.82±3.84)%,CD4⁺/CD8⁺(1.95±0.28)% vs. (1.54±0.25)%]均优于对照组(P＜0.05)。两组不良反应比较,差异均无统计学意义(P＞0.05)。结论中晚期PLC患者采取TACE术联合仑伐替尼治疗效果显著,可改善患者肿瘤标志物、肝功能指标和免疫状态,病死率较低。

关键词: 经动脉化疗栓塞术, 仑伐替尼, 阿帕替尼, 中晚期原发性肝癌

Abstract: Objective To evaluate the effects of TACE combined with lenvatinib or combined with apatinib in treating advanced primary liver cancer (PLC). Methods Eighty-five patients (2022.01-2023.12) with middle- to late-stage PLC admitted to the Affiliated Cancer Hospital of Nantong University were selected and divided into two groups according to their treatment regimens. Forty-two patients in the control group received TACE combined with apatinib, while forty-three patients in the observation group were treated with TACE combined with lenvatinib. Results TheObjective remission rate (ORR 60.47%) and disease control rate (DCR 74.42%) in the observation group were significantly better than those in the control group (ORR 35.71%; DCR 52.38%) (P<0.05). After treatment, the level of tumor markers [CEA(13.36±2.47)ng/mL vs. (19.63±3.14)ng/mL,CA125(52.63±6.89)U/mL vs.(58.49±8.69)U/mL,VEGF(292.69±23.46)ng/mL vs. (341.63±28.48)ng/mL], liver function [TBil(16.85±3.89)μmol/L vs. (21.78±4.02)μmol/L,ALT(42.63±6.52)U/L vs. (53.69±7.25)U/L,VEGF(38.52±4.69)U/L vs. (48.20±5.06)U/L]and immune function[CD4⁺(46.32±4.87)% vs. (42.69±4.38)%,CD8⁺(22.36±3.25)% vs. (26.82±3.84)%,CD4⁺/CD8⁺ ratio(1.95±0.28) vs. (1.54±0.25)] in the observation group were better than those in the control group (P<0.05). Comparing the adverse events of the two groups, the differences were not statistically significant (P>0.05). Conclusion TACE combined with lenvatinib showed better clinical outcomes, improved tumor and immune markers, and enhanced liver function compared to TACE combined with Apatinib in patients with advanced PLC, with no significant difference in adverse reactions.

Key words: Transarterial chemoembolization, Lenvatinib, Apatinib, Intermediate and advanced primary liver cancer

姚敏, 杨军军, 郭小红, 徐爱兵. TACE术联合仑伐替尼与联合阿帕替尼治疗中晚期原发性肝癌的效果及安全性比较[J]. 肝脏, 2025, 30(12): 1647-1651.

YAO Min, YANG Jun-jun, GUO Xiao-hong, XU Ai-bing. Effect and safety of TACE combined with lenvatinib mesylate and combined with apatinib in the treatment of intermediate and advanced primary liver cancer[J]. Chinese Hepatolgy, 2025, 30(12): 1647-1651.

/ 推荐

参考文献

[1] 杨佳琪,骆佳辉,闾允,等. 卡瑞利珠单抗联合FOLFOX4治疗与FOLFOX4单独治疗中晚期原发性肝癌的效果及安全性对比[J]. 实用癌症杂志,2024,39(8):1325-1329.
[2] 陈紫薇,刘华华. 中药扶正消积汤联合介入治疗中晚期原发性肝癌临床观察[J]. 中西医结合肝病杂志,2024,34(5):448-450.
[3] 杜尚云,翁莉,武敏. TACE联合卡瑞利珠单抗治疗中晚期原发性肝癌患者临床疗效研究[J]. 实用肝脏病杂志,2023,26(1):116-119.
[4] 王惠,凌青霞. 阿帕替尼联合TACE治疗中晚期肝癌患者的疗效及对其血清AFP,CA125,CA199水平的影响[J]. 医学临床研究,2023,40(2):183-186.
[5] 周延平,杜峰,王帅. 仑伐替尼联合肝动脉化疗栓塞治疗肝癌的疗效及预后影响因素分析[J]. 海南医学,2024,35(20):2925-2928.
[6] 吴晋周,靳建旭. 阿帕替尼联合替吉奥治疗肝动脉化疗栓塞术后的原发性肝细胞癌的疗效研究[J]. 中国医药导刊,2023,25(9):952-956.
[7] 中华人民共和国国家卫生健康委员会医政司. 原发性肝癌诊疗指南(2024年版)[J]. 中华肝脏病杂志,2024,32(7):581-630.
[8] 冯奉仪. 实体瘤新的疗效评价标准(解读1.1版RECIST标准)[C]. 中华医学会;中国抗癌协会,2009.
[9] National Cancer Institute. Common terminology criteria for adverse events (CTCAE) v4.0[S]. 2009.
[10] 钟桂红,韩建,徐樟琦,等. TACE联合卡瑞利珠单抗治疗中晚期原发性肝癌患者的临床效果[J]. 临床医学工程,2023,30(10):1353-1354.
[11] 熊诗峰,喻国锋. 经导管动脉栓塞化疗联合阿帕替尼治疗老年中晚期肝癌患者的疗效[J]. 癌症进展,2023,21(24):2732-2734.
[12] 吴福勇. TACE联合仑伐替尼应用于中晚期肝癌患者的临床效果及对血清肿瘤标志物水平的影响[J]. 中外医疗,2024,43(24):51-54.
[13] Wang T, Tang J, Yang H, et al. Effect of apatinib plus pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone on platinum-resistant recurrent ovarian cancer: The APPROVE randomized clinical trial[J]. JAMA Oncol, 2022,8(8):1169-1176.
[14] 王保江,丛鹏. 经导管动脉化疗栓塞联合仑伐替尼治疗中晚期原发性肝癌的有效性与安全性:meta分析[J]. 中国普外基础与临床杂志,2023,30(12):1444-1451.
[15] 隋永博,陈金玲,张重阳,等. 肝动脉化疗栓塞术联合阿帕替尼治疗中晚期肝癌的临床观察[J]. 中西医结合肝病杂志,2024,34(2):123-125.
[16] 朱心睿,张晓赟,彭伟,等. 中性粒细胞/淋巴细胞比值对接受经肝动脉化疗栓塞+甲磺酸仑伐替尼+卡瑞利珠单抗治疗的不可切除肝癌的预后预测意义[J]. 中国普外基础与临床杂志,2021,28(11):1426-1433.
[17] 赵晓辉,姚全军,黎海亮,等. 经肝动脉化疗栓塞术联合靶向/免疫治疗在中晚期肝细胞癌中的应用进展[J]. 临床肝胆病杂志,2022,38(12):2855-2858.
[18] 王颖栋,丁海斌,黄子超,等. 华蟾素联合仑伐替尼治疗经动脉化疗栓塞术后原发性肝癌患者的近期疗效[J]. 医学临床研究,2022,39(1):9-12.
[19] 刘耀鸿,林宜圣,杨荣焕,等. 仑伐替尼联合肝动脉化疗栓塞术对中晚期原发性肝癌患者近期疗效、T淋巴细胞免疫功能及预后的影响[J]. 临床误诊误治,2022,35(7):60-63.